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Abstract: A number of epidemiologic studies on organochlorines (OCs) and breast cancer
risk have been published. The majority (n = 18) measured OCs in adipose tissue, primarily
from mammary biopsies in cancer cases and controls with benign breast disease, and studied
incident disease. Seven of these studies each included fewer than 50 cases and controls and
had limited capacity for covariate adjustment. Eleven studies used serum samples collected
from 6 months to 25 years prior to diagnosis. An additional 13 studies (2 with some overlap)
used serum collected at or after diagnosis. Regardless of the medium used to measure OC
levels, studies conducted to date do not provide consistent evidence that any of the OCs ex-
amined thus far play a role in the initial breast cancer risk. This paper provides a compound
specific review with discussion of how the lack of evidence for adverse effects might be ex-
plained by factors related to study design, or by variation in risk across subgroups. 
The sum of the evidence does not implicate any OC compound as significantly related
to risk of occurrence of breast cancer. The evidence base is greatest for dichlorodiphenyl-
trichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE). Limited research has
been done on individual polychlorinated biphenyls (PCBs) and their isomers. The studies of
OC exposure reflect current exposure levels of chemicals banned as long ago as 20 years.
Although the information is extremely limited and not without major design flaws, the asso-
ciation between OCs and disease severity and progression is interesting and worthy of fur-
ther examination.
More studies are needed on OCs other than DDTs in developing countries where use
is more recent or continuing, especially given that most estrogenic OCs are not persistent. It
is possible that other pathways may be involved, including activity related to cytochrome
P450 (CYP) and glutathione-S-transferase (GST); there is limited research to date on this hy-
pothesis. In developed countries, a body mass index (BMI)/weight loss model may warrant
further analysis, perhaps using existing data. 
OC exposures cannot reliably be related to trends in breast cancer incidence, as other
known risk factors for breast cancer, such as childbearing and lactation, have changed along
with OC residues during this timeframe. Changes in screening and treatment over time also
complicate making such links. Ecologic data relating high-exposure countries to high breast
cancer mortality rates do not suggest a strong link. Breast cancer rates are not generally
higher in parts of the world with high DDE levels. Countries with relatively similar levels of
PCBs, such as Great Britain and Japan, have very different breast cancer rates.
*Report from a SCOPE/IUPAC project: Implication of Endocrine Active Substances for Human and Wildlife (J. Miyamoto and
J. Burger, editors). Other reports are published in this issue, Pure Appl. Chem. 75, 1617–2615 (2003).
‡Corresponding author 
As OCs are present in the environment as mixtures of correlated isomers and metabo-
lites, it may be difficult to distinguish possible causal links from associations in which meas-
ured compounds are merely markers of other underlying exposures. For highly correlated
compounds, traditional adjustment strategies may not be feasible. More complex analytical
strategies may help to isolate potentially relevant isomers. 
INTRODUCTION
Although a variety of other compounds, including pharmaceutical agents (e.g., oral contraceptives, ta-
moxifen) and phytoestrogen-containing foods (e.g., soybeans, cabbage) may mimic or modulate estro-
gen activity, chemicals produced for industrial or agricultural use have been the primary focus of re-
search on endocrine disruptors and human health [1]. These chemicals, known as organochlorine
compounds (OCs), comprise a diverse group of compounds, including: (i) pesticides (e.g., DDT, aldrin,
dieldrin, chlordane, heptachlor epoxide, hexachlorocyclohexane, hexachlorobenzene, methoxychlor);
(ii) industrial chemicals (e.g., PCBs used in lubricants, coolants, sealants, and pesticides; mirex used as
a fire retardant coating and a pesticide); and (iii) breakdown products of these chemicals. OCs are
lipophilic and persist in the environment. Thus, despite the bans, exposure to many OC isomers and
metabolites endures decades later as a result of residues in soil, water, dust, and foods, most notably in
fat-containing animal products such as meats, fish, and dairy products [2–4]. Environmental exposure
to these organochlorines has been postulated to increase the risk of breast cancer through potential es-
trogenic activity [5–7]. Not all OCs possess estrogenic activity, and some, depending upon the internal
milieu, may have antiestrogenic or anticarcinogenic effects [8–14]. Nonetheless, OCs may also increase
the risk of breast cancer via other mechanisms, including promotion of tumor growth [15–17] and mod-
ulation of enzyme activity [8,18,19]. 
Peak use of most OC chemicals occurred in the 1950s and 1960s, some three decades after their
introduction [20,21]. Most were banned in the United States and other industrialized countries in the
early 1970s (DDT) or late 1970s (PCBs, mirex, benzene hexachloride [BHC], and hexachlorobenzene
[HCB]) [4,22]. Use of a number of these chemicals continues in many developing countries. OC levels
in human tissues and foods in these countries are several times higher than in the United States and
Europe [2,23].
Data from North America and Europe indicate that residues of most OCs in human adipose tis-
sue, breast milk, and serum have declined substantially over the past 20 years, but that more persistent
isomers and metabolites are still present in detectable amounts [4,24–28]. DDT-related isomers appear
to have decreased more rapidly than PCBs and some other OCs such as HCB [24,28]. Given their ubiq-
uitous presence in the environment and the continued use of some OCs in developing countries, it is of
interest to determine whether these compounds are indeed related to the risk of breast cancer. Early
studies yielded conflicting results. They also generated hypotheses that might help to explain inconsis-
tencies, such as the possibility of variation related to subgroups defined by tumor estrogen receptor
(ER) status [29], lactation history [22], or ethnicity, perhaps as a result of higher exposure [30]. This
paper will assess whether various aspects of study design may be related to inconsistent results, and will
review whether studies published to date support the hypotheses related to at-risk subgroups. We em-
phasize compounds that have been the focus of most research to date, namely: (i) DDT-related com-
pounds, including DDE, a common persistent metabolite of found in the food chain and the environ-
ment; and (ii) PCBs. We also review the more limited evidence available for several other OCs. 
OVERVIEW OF RESULTS
Epidemiologic studies of OCs and breast cancer risk published to date are summarized in Table 1. The
majority (n = 20; seven of which incorporate populations at least partially included in other reports)
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measured OCs in adipose tissue, primarily from mammary biopsies in cancer cases and controls with
benign breast disease (BBD). Eight of these studies each included fewer than 50 cases and controls and
had limited capacity for covariate adjustment. Ten studies (three with overlap in populations) used
serum samples collected from 6 months to 25 years prior to diagnosis. An additional 13 studies (two
with some overlap) used serum collected at or after diagnosis. 
As summarized in Table 1 and detailed below, regardless of the medium used to measure OC lev-
els, studies conducted to date do not provide consistent evidence that any of the OCs examined thus far
play a role in the initial breast cancer risk. A compound-specific review follows with discussion of how
the lack of evidence for adverse effects might be explained by factors related to study design, or by vari-
ation in risk across subgroups. 
DDT/DDE
p,p′-DDT is only weakly estrogenic, but persists in the food chain [2,11,13]. Of 10 studies reporting
multivariate-adjusted ORs, only one [31] found elevated risk associated with adipose or serum levels of
p,p′-DDT (Table 2). Another eight studies compared mean levels of p,p′-DDT but incorporated limited
covariate adjustment. One of these [32] reported significantly higher levels in cases, after adjusting for
age and BMI. o,p′-DDT—a more estrogenic but less persistent isomer—has not been studied epidemi-
ologically because even studies using serum collected in the 1970s, when levels were higher, had too
few participants with detectable levels to analyze associations separately [33]. A number of studies
[31,33–37] examined associations with total DDT, estimated as the sum of p,p′-DDT and several
metabolites. None reported evidence of adverse effects in relation to high levels of the sum of these
DDT metabolites. 
Most studies of DDE have examined p,p′-DDE, the main persistent metabolite of DDT. Since this
compound, which is not estrogenic, is found in foods, elevated levels may not be the result of direct ex-
posure to p,p′-DDT [11,37,38]. Although a few studies conducted from 1992 to 1994 [29,39], in ER
positive [ER+] tumors; [40] suggested possible increased risk associated with p,p′-DDE, other early ex-
ploratory studies did not find increased risk [41,42], and the majority of studies since that time have re-
ported inverse or null associations (Table 3). Two of the three initial studies reporting elevated p,p′-DDE
in subjects with breast cancer were very small (≤20 cases) and unable to conduct adequate multivariate
adjustment [29,39]. Positive associations reported by [40] were based on cases diagnosed within
6 months of serum collection and were not confirmed in a follow-up using cases with similar OC lev-
els, diagnosed >6 months after enrollment [25]. Adjustment for serum lipids, omitted in the first analy-
sis, did not influence results of the second study. 
To date, 27 moderate to large (i.e., at least 50 cases) studies with multivariate adjustment have ex-
plored associations between p,p′-DDE and breast cancer. Other than the early studies referenced above,
only one other study ([23] in a Mexico City study of parous women) has reported significant positive
associations overall. Two additional studies reported significant positive associations in different sub-
groups ([43] in ER negative [ER–] tumors; [30] in blacks but not whites or Hispanics). One small study
[44], using adipose tissue samples collected from 1987 to 1989 and analyzed without adjustments did
report significantly higher means of the more estrogenic but short-lived metabolite o,p′-DDE in cases
than controls. 
In summary, the majority of studies, regardless of medium or study size, showed no negative im-
pact of DDT or DDE on risk of breast cancer. Risk was not more likely to be apparent in populations
with higher mean concentrations of DDT or DDE. In fact, many studies show risk ratios below 1, as
above 1 (as seen on Figs. 1a and 1b). 
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Four of 17 published studies on total PCBs and breast cancer risk reported significant positive associa-
tions (Table 4). The report of Wolff et al. [40] showed a significant positive association that was not
replicated in the follow-up study [25]. In the three other studies, elevated risk was limited to various di-
verse population subgroups (Moysich et al. [22] in parous never-lactators; Millikan et al. [45] in blacks,
particularly if obese; Laden et al. [46] in nulliparous women). 
Examining total PCBs may mask variation in congener-specific effects, as some of the 209 con-
geners are thought to be estrogenic (type 1a), while others appear to be antiestrogenic (types 2a and b),
or to have no estrogenic activity (type 1b, based on groupings proposed by Wolff and Toniolo [8]; Wolff
et al. [47]). Net effects of PCB mixtures may vary depending on relative concentrations of these differ-
ent congeners [47,48]. The low-chlorination, potentially estrogenic congeners of group 1a are not per-
sistent, as they are readily metabolized and eliminated [48]. However, the two studies [44,49] reporting
means for congeners in this group did not find significant differences between cases and controls
(Table 5). Given their rapid elimination, retrospective studies may not be reliable for assessing any long-
term effects of these congeners. The prospective studies have had few subjects with detectable levels of
1a congeners [33]. 
M. A. MENDEZ AND L. ARAB
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Fig. 1 (a) DDT and breast cancer risk. (b) DDE and breast cancer risk.
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Group 1b PCBs are weak phenobarbital inducers and are more persistent. Published studies have
not reported positive associations of these congeners as a group [24] or individually (multivariate re-
sults—[24,50–52]; means—[29,32,43,49]). 
Congeners in group 2a are thought to be antiestrogenic and immunotoxic; those in group 2b ap-
pear to have limited dioxin activity. The highly persistent congeners in group 3 are thought to induce
cytochrome P450 and phenobarbital activity. No studies have reported elevated risk associated with the
sum of the congeners from these groups. A few studies have reported elevated risk associated with indi-
vidual congeners in each group (e.g., PCBs 118, 138, 99), but results have been inconsistent (Table 5). 
Two studies compared PCB congeners classified as high- vs. low-chlorination in relation to breast
cancer and again found ambiguous results. Wolff et al. [53] reported evidence of elevated risk only for
low-chlorination congeners. In contrast, Millikan et al. [45] reported greater risk associated with high-
chlorination congeners. 
Other OCs
The few studies examining other OCs in relation to breast cancer risk have, for the most part, found no
association (Table 6). No studies have reported significant increased risk associated with chlordane
metabolites, including cis-nonachlor (CN), trans-nonachlor (TN), oxychlordane (OXY), and heptachlor
epoxide (HCE) [24,43,50–54]. Mixed results have been reported for dieldrin, mirex, HCB, and HCH
(or b-BHC; see Table 6). No studies on endosulfan were found. 
STUDY DESIGN FACTORS
Adipose tissue vs. blood
As OCs are lipophilic, adipose tissue sample stores are thought to provide a better index of long-term
exposure than blood-based measures. Strong correlations between adipose tissue and lipid-adjusted
serum levels of DDE have been reported in some (r = 0.8, [55]) but not all (r = 0.4, [64]) studies.
Similar, low correlations between adipose and lipid-adjusted serum levels of PCBs have been seen (e.g.,
r = 0.4 for PCB 153; [55]). 
Differences in these measures do not, however, appear to explain study inconsistencies, as results
using each medium have been heterogeneous. For example, significant positive associations with DDE
and breast cancer were reported for: (i) one of six reports from large studies using adipose tissue sam-
ples; (ii) two of 10 studies using prospective serum samples; and (iii) none of 10 studies based on ret-
rospective serum (Table 2). 
Study populations—using benign breast disease (BBD) controls
Most studies based on adipose tissue used BBD patients as controls because it is more difficult to ob-
tain adipose tissue samples from disease-free subjects (Table 1). If OCs contribute to the risk of BBD,
this strategy may bias results toward the null. However, studies using alternative control groups also
failed to observe positive associations. Using patients presenting for breast reduction surgery, Bagga et
al. [34] found null associations for various DDTs. Inverse associations with DDE were reported by van’t
Veer et al. [56] in a study based on gluteal adipose tissue samples and population-based controls.
Studies that excluded [57–60] or limited [32] the proportion of BBD controls with evidence of atypia
found no strong evidence of adverse effects. Wolff et al. [53] also found no difference in results between
BBD and non-BBD non-cancer controls, suggesting that the predominance of BBD controls is not the
reason for lack of a measurable detrimental effect. 
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Timing of exposure measurement vs. use of OC chemicals
The majority of studies in industrialized countries have measured OC residues in biological samples
collected from adults in the 1980s and 1990s, well after most source chemicals were banned. Given
half-life estimates on the order of 7 to 11 years for DDE and PCBs [53], residues measured in these
studies may largely reflect exposure to persistent but less estrogenic OCs (such as p,p′-DDE and high-
chlorination PCB congeners), rather than long-term exposure to estrogenic but less persistent com-
pounds such as DDT, dieldrin, and low-chlorination PCBs [11,13,48]. Therefore, recent measures of
OCs may not be good estimates of past exposure to estrogenic compounds. 
Direct estimates using samples obtained closer to the period when chemical sources remained in
use should be more reliable for identifying any adverse effects of less persistent OCs, as long as sam-
ples were stable and analytic measures were sensitive enough. In industrialized countries, four of five
prospective studies used blood collected as early as the 1960s and 1970s. These did not find overall ad-
verse effects of DDTs, PCBs, or several other OCs [24,30,33,35]. Concentrations of DDE and DDT in
these samples were relatively high (Tables 2 and 3). The one study showing effects that examined
p,p′-DDT in a population-based Danish study [31] used repeated serum measures and adjusting for
weight change. No other studies have incorporated repeated measures of OC exposure, and few have
included measures of weight change (see Table 1). 
Of the studies examining associations between DDT, DDE, and breast cancer risk in countries
where use of DDT continues (Table 2), some based in Mexico City [23,61] and in Vietnam [37] found
lower mean levels of p,p′-DDT in breast cancer cases vs. controls. No association between DDE and
breast cancer in hospital-based case-control studies were noted in Vietnam [37], Mexico City [61], or
in a population-based study in Brazil [62]. An anomalous result was seen in a population-based study
of parous women in Mexico City [23] that reported strong and significant positive associations with
DDT-adjusted levels of serum DDE. The authors hypothesized that adjusting for DDT provided better
estimates of long- vs. short-term exposure to DDE. It is not clear whether they limited their adjustment
model to low-persistence DDT isomers. Without this adjustment, multivariate associations were not sig-
nificant (OR for highest vs. lowest quartile 2.16, CI 0.85–5.50 vs. 3.81, CI 1.14–2.8). 
It is surprising that, although timeframes for the Mexico City studies overlapped (1990 to 1995
for Romieu et al. [23]; 1994 to 1996 for Lopez-Carillo et al. [61]), serum DDE was five times higher in
the study reporting positive associations (lipid-adjusted means in cases/controls were 3840/2510 vs.
563/506 nanograms per gram [ng/g]). It is not clear to what extent discrepancies between the two
Mexico City studies may reflect true differences in DDT and DDE exposure, metabolism, temporal
changes, or differences in laboratory techniques. 
Mobilization and elimination of OCs—weight change, adiposity, and lactation
A number of factors, including body fat burden, weight changes, and lactation history, may influence
the dilution, mobilization, and elimination of fat schedule substances stored in the body [25,31,63,64]. 
Weight loss over a 5-year period was associated with significant declines in DDE and several
PCBs, while weight gain was associated with larger increases in PCBs as compared to weight-stable
subjects [31]. Self-reported losses or gains of >5 pounds in the past year was associated with signifi-
cantly lower levels of DDE as compared to weight-stable women when examined cross-sectionally [63]. 
Greater adiposity may result in more dilute residues, particularly in adipose tissue [25,53,65].
Wolff and Anderson [65] proposed a pharmacokinetic model in which one or two half-lives after sig-
nificant uptake elimination may become more complete in lean subjects than in those with a greater adi-
pose tissue reservoir. Under this model, BMI should be treated as a modifier rather than as a confounder. 
Lactation may also influence OC body burden, as breast milk is thought to be an important route
of excretion of OCs. High concentrations of OC residues are detected in breast milk, and lactation has
been associated with lower OCs [40,64,66]. Indeed, Wolff et al. [40] reported that adjusting for lacta-
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tion status increased coefficients for DDE exposure by 57 % (from 0.051 ± 0.022 to 0.080 ± 0.030).
Limited data also suggest that higher DDE is associated with reduced duration of breastfeeding [67],
and several studies found that OCs were associated with higher risk of breast cancer among nulliparous
women, or parous women who never breastfed than lactators ([22]–HCB; [50]–Mirex; [45,46]–total
PCBs; [54]–chlordane). These findings are consistent with the hypothesis that breastfeeding may help
to reduce the OC burden during a period of increased susceptibility to breast cancer.
Dietary confounders
Few studies have included dietary covariates (see Table 1). Dietary fat may be a confounder, given that
fat-containing foods are important sources of exposure to persistent OC metabolites [3]. However, re-
sults of studies that adjusted for fat intakes did not differ from those that did not [50,52,57–59].
Furthermore, the role of dietary fat in breast cancer is unclear [68]. Dietary phytoestrogens may mod-
ify or confound associations, perhaps by inhibiting estrogenic action of OCs [69,70] A number of di-
etary phytoestrogens (e.g., genistein) appear to be more potent estrogens than typical OCs [71]. No
studies to date have reported accounting for dietary phytoestrogens, whose role in breast cancer etiol-
ogy is also uncertain [72,73]. 
Consideration of adjustment for these variables is essential for approximating cumulative or past
exposure based on single measures of OC residues. While most studies have adjusted for BMI, few have
accounted for lactation history or weight change (see Table 1 for details) [29,31,35,56]. No study has
simultaneously considered all three factors. 
POSSIBLE HIGH-RISK SUBGROUPS
Menopausal status: It has been suggested that postmenopausal women because of low circulating es-
trogen levels may be more susceptible to risk factors that influence the hormonal milieu [72]. A few
studies have observed stronger associations in post-menopausal than in pre-menopausal women for
DDT ([23] for DDT) or total PCBs ([49], especially if ER+). The majority of studies have not found
strong associations among postmenopausal women for DDT/DDE [22,25,30,32,33,45,49,50,53,
54,56,57,60,61,74], total PCBs [22,25,32,45,53,60] or other OCs such as HCB, mirex, and chlordane
metabolites [22,40,50,52,54,58,59]. In fact, several studies found stronger associations among pre-
menopausal than postmenopausal women for DDE [35], total PCBs [35], and selected PCB congeners
[50].
Assessing the significance of any differences in risk by menopausal status is complicated by dif-
ferences in exposure patterns of younger vs. older women. A cohort effect in older women having ex-
perienced greater childhood and lifetime exposures may be responsible for what might be considered
an age-related or lifetime accumulation effect when compared with younger women. Among younger
women, whose exposure during peak use of these chemicals was limited to childhood and adolescence,
adult OC residues may largely reflect ongoing food-borne exposure to persistent metabolites. Direct ex-
posure to industrial and agricultural chemicals in the past likely explains why OC levels are higher in
older than in younger women (e.g., [27]). However, exposure in postmenopausal women may have been
qualitatively different from that in younger women: during peak chemical use in the 1950s and 1960s,
these women were adults. 
ER status
Consistent with the hypothesis that the hormones may be more involved in the etiology of ER+ than
ER– tumors [75], Dewailly et al. [29] found that DDE, PCB 99, and trans-nonachlor were associated
with ER+ but not ER– tumors (see Tables 3, 4, and 7). Liljegren et al. [49] also found significantly
higher risk associated with HCB and several PCBs (77, 126, 169) among ER+ tumors, especially in
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postmenopausal women. Other studies have not confirmed these findings. Woolcott et al. [43] found
somewhat stronger associations between DDE, total PCBs, trans-nonachlor, b-HCH, and several PCB
congeners in ER– tumors (see Tables 3–5). Although Helzsouer et al. [35] found higher associations
with DDE in ER+ tumors using serum collected in 1989, associations were higher in ER– tumors using
serum from 1974. Numerous studies reported similar associations with DDE [24,25,45,49,52–54,74],
PCBs [24,25,35,45,52–54,60,74], and other OCs [43,52,54,58,59] regardless of ER status. 
Ethnicity and threshold effects: Krieger et al. [30] and Millikan et al. [45] reported somewhat
stronger associations between serum DDE, total PCBs, and breast cancer risk among African
Americans than other ethnic groups (whites and Asians). They hypothesized that the higher associations
might be attributable at least in part to higher exposure levels. Yet there were no differences in associ-
ations among African Americans, whites, and Hispanics in a report by Wolff et al. [53], in which OC
levels were similarly elevated among blacks. There was also no association with breast cancer risk in
other studies in whites with similar serum OC levels [25,35]. However, associations between breast can-
cer and DDE were significant in the studies with the highest serum levels [23], after adjustment for
DDT) and adipose levels [29,39]. Research in multiethnic settings with high levels of DDE is needed
to confirm this hypothesis. 
Genetic polymorphisms
In addition to mimicking estrogen activity, OCs are inducers of detoxification and drug-metabolizing
enzymes [76,77]. Variation in genotypes for drug-metabolism genotypes such as cytochrome P4501A1
(CYP1A1) and detoxification enzymes such as glutathione-S-transferase µ (GSTM1) may be associated
with susceptibility to OCs. Moysich et al. [76] found elevated breast cancer risk among subjects with
high total PCBs and either heterozygous (isoleucine: valine) or homozygous valine subtypes for
CYP1A1. Compared to the isoleucine homozygous group with low PCBs, this group was 2.9 times
more likely to have breast cancer after multivariate adjustment (95 % CI 1.2–7.5). For the isoleucine
homozygous group with high PCB exposure, the OR was 1.08 (CI 0.6–1.9). However, Helzsouer et al.
[35] did not find strong evidence of modified susceptibility to the effects of DDE or total PCBs associ-
ated with polymorphisms in GSTM1, GSTT1, GSTP1, COMT, or CYP17. 
OCCUPATIONAL STUDIES
Few studies on occupational exposure and breast cancer among women have been published. Both the
exposure route and the estrogenicity of isomers to which women are exposed occupationally are likely
to differ substantially from food-borne exposure to persistent OCs. Studies of pesticide workers have
not reported an increased breast cancer incidence or mortality cancer associated with this industry
([78,79]; earlier studies reviewed by Adami et al. [80]). While farmworking per se was not associated
with increased risk, Duell et al. [21] reported increased risk of breast cancer associated with women
who were present in fields during or shortly after pesticide application (OR = 1.8, 95 % CI = 1.1–2.8).
Risk was also elevated among women who reported not using protective clothing while applying pesti-
cides (OR = 2.0; 95 % CI = 1.0–4.3) but not among those who reported using protective clothing
(OR = 0.8; 95 % CI = 0.4–1.8). As no consistent exposure-related effects are seen in other studies, this
may reflect other farm-based exposures or characteristics of the lifestyle, rather than OC exposure. 
OCS AND BREAST CANCER SEVERITY AND PROGRESSION 
Although laboratory data suggest that OCs may act as tumor promoters [16], the hypothesis that OCs
may be related to the progression rather than the incidence of breast cancer has been explored in very
few studies, so less is known on this topic [51]. Associations with various measures of stage, aggres-
siveness, and tumor markers have been reported in six studies to date (see Table 7). These studies—all
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conducted in industrialized countries using recent OC samples—have not reported associations between
DDT/DDE and breast cancer survival, stage, aggressiveness, or tumor marker (p53 or erbB-2)
[45,51,53,81]. Positive associations with PCBs and various measures of progression, severity, or sur-
vival have been reported in some studies [51,81], but weak or null associations have been reported in
other [43,45,52,53] studies. Gammon et al. [54] did not find positive associations between stage at di-
agnosis (in situ vs. invasive disease) and concentrations of DDE, PCBs, or chlordane. Limited data sug-
gest that other OCs may be associated with severity [51] and survival [81]. More data are needed be-
fore conclusions can be drawn, but this is an area deserving further study.
SUMMARY AND RECOMMENDATIONS
The sum of the evidence does not implicate any OC compound as significantly related to risk of oc-
currence of breast cancer. The evidence base is greatest for DDT and DDE. More limited research has
been done on individual PCBs and their isomers. The studies of OC exposure reflect current exposure
levels of chemicals that may have been banned for 20 years. Despite long half-lives (of 10 years) in adi-
pose tissue, samples were generally collected 30 years after the peak exposure times. However, given
ongoing exposure to persistent, nonestrogenic metabolites in foods, it is not certain that ranking of ex-
posures using these samples is an accurate measure of past exposure to those compounds thought to in-
crease risk. 
More studies are needed on OCs other than DDTs in developing countries where use is more re-
cent or continuing, especially given that most estrogenic OCs are not persistent. The possibility that OC
exposure in excess of certain thresholds may be related to risk cannot be ruled out based on existing
data. It is possible that other pathways that influence susceptibility may be involved, including activity
related to CYP and GST; limited research is available to date on this hypothesis. Additionally, the
BMI/weight loss model may warrant further analysis, perhaps using existing data. 
OC exposures cannot reliably be related to trends in breast cancer incidence, as other known risk
factors for breast cancer, such as childbearing and lactation. Changes in screening and treatment over
time also complicate making such links. Ecologic data relating high-exposure countries to breast can-
cer mortality rates do not suggest a strong link. As noted by Rogan [82], “in general, breast cancer rates
are not higher in parts of the world with high DDE levels (the People’s Republic of China, India, and
Guatemala), and countries with relatively similar levels of PCBs (Great Britain and Japan) have very
different breast cancer rates.”
Although the information is extremely limited and not without major design flaws, the associa-
tion between disease severity and progression is interesting and worthy of further examination. 
As OCs are present in the environment as mixtures of correlated isomers and metabolites, it may
be difficult to distinguish possible causal links from associations in which measured compounds are
merely markers of other underlying exposures. Few studies [23,36,40,52,83] have reported adjusting for
other OCs. For highly correlated compounds, traditional adjustment strategies may not be feasible.
More complex analytical strategies, such as those used by Holford et al. [83], may help to isolate po-
tentially relevant isomers. 
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